Mineralys Therapeutics, Inc.
MLYSNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | −$170.6M | −$192.4M | −$84.7M | −$31.5M |
| Net income | −$154.7M | −$177.8M | −$71.9M | −$29.8M |
| Total assets | $661.8M | $205.9M | $251.6M | $114.4M |
| Total liabilities | — | — | — | — |
| Equity | $646.7M | $191.3M | $241.2M | −$52.3M |
| EPS (diluted) | $-2.29 | $-3.66 | $-1.99 | $-5.77 |
| Shares out. | 49.8M | 49.6M | 41.1M | 6.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −23.9%
- Return on assets
- −23.4%
- Return on capital (ROCE)
- −26.4%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $12.98
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −1.8%clean
- Piotroski F-Score
- 3/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 1 good- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Rodman David MalcomOfficer — Chief Medical Officer | May 18, 2026 | Option exercise | 417 | $15.44 |
| Rodman David MalcomOfficer — Chief Medical Officer | May 11, 2026 | Option exercise | 2,171 | $16.00 |
| Rodman David MalcomOfficer — Chief Medical Officer | Apr 17, 2026 | Option exercise | 416 | $15.44 |
| Rodman David MalcomOfficer — Chief Medical Officer | Apr 13, 2026 | Option exercise | 6,349 | $1.08 |
| Congleton JonOfficer — Chief Executive Officer | Apr 13, 2026 | Sell | 15,730 | $26.83 |
| Rodman David MalcomOfficer — Chief Medical Officer | Apr 9, 2026 | Option exercise | 2,170 | $16.00 |
| Congleton JonOfficer — Chief Executive Officer | Mar 31, 2026 | Sell | 19,364 | $25.50 |
| Karydas DaphneDirector | Mar 31, 2026 | Option exercise | 3,000 | $12.02 |
| Ra Capital Management, L.P.Director | Mar 27, 2026 | Buy | 310,700 | $23.67 |
| Rodman David MalcomOfficer — Chief Medical Officer | Mar 17, 2026 | Option exercise | 417 | $15.44 |
| Rodman David MalcomOfficer — Chief Medical Officer | Mar 12, 2026 | Option exercise | 6,348 | $1.08 |
| Rodman David MalcomOfficer — Chief Medical Officer | Mar 9, 2026 | Option exercise | 2,171 | $16.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.0M | 8.2 | +5.8% |
| Apr 30, 2026 | 8.5M | 9.8 | -2.8% |
| Apr 15, 2026 | 8.8M | 6.5 | +4.9% |
| Mar 31, 2026 | 8.4M | 5.7 | -6.5% |
| Mar 13, 2026 | 8.9M | 6.7 | -6.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 22, 2026
- Results of operationsMay 6, 2026
- Results of operationsMar 12, 2026
- Regulation FD disclosure · Other material eventMar 9, 2026
- Regulation FD disclosure · Other material eventJan 6, 2026
- Results of operationsNov 10, 2025
- Other material eventSep 3, 2025
- Other material eventSep 2, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.